Faculty Opinions recommendation of Tiotropium bromide step-up therapy for adults with uncontrolled asthma.

Authors:

Abstract
I found this article very interesting since it suggests a new treatment approach for adults with uncontrolled asthma on daily low-dose inhaled corticosteroids (ICS). The current National Asthma Education and Prevention Program (NAEPP) guidelines for this scenario recommend adding a long-acting beta-agonist (LABA) or increasing the dose of the ICS. In this article, Peters et al. suggest that the addition of tiotropium bromide (a long-acting anticholinergic agent approved for the treatment of chronic obstructive pulmonary disease), is an additional effective treatment option. The study population included adults with asthma not adequately controlled with a low-dose ICS (beclomethasone at a dose of 80ug twice daily). The investigators used a triple-blind, placebo-controlled, three-way crossover study to investigate the addition of tiotropium bromide to an ICS compared with a doubling of the dose of the ICS (primary superiority comparison) or the addition of the LABA (secondary noninferiority comparison). Primary outcome was morning peak expiratory flow (PEF) and additional clinical outcomes served as secondary outcomes. The addition of tiotropium resulted in a greater improvement in morning PEF and in most of the secondary clinical outcomes compared to doubling the dose of the ICS. The addition of tiotropium was also noninferior to the addition of LABA for the primary outcome and was actually superior to doubling the dose of the ICS for the improvement of prebronchodilator forced expiratory volume (FEV)1 and for FEV1 after albuterol treatment. In an additional set of analyses, it was found that adding LABA was superior to doubling the dose of ICS for the primary outcome and for most of the secondary outcomes (this confirmed previous findings from multiple studies). This study is important since it suggests an innovative treatment approach which is important in view of the recent FDA recommendation to minimize LABA treatment. As noted by an editorial of this article {1}, this study had a short follow-up period and, therefore, additional studies will be needed to monitor effect on asthma exacerbations and to address potential safety concerns on tiotropium treatment. In addition, we will note that these findings cannot be extrapolated to childhood asthma.